Author name: Leonardo Arias

The revamp comes nearly two years after the department under the Biden administration first restructured the HHS’ technology functions.

Durante los últimos años, el modelo agrivoltaico ha ido ganando protagonismo en el panorama energético europeo, con aplicaciones que van desde los cultivos tradicionales hasta el pastoreo o la apicultura.   A este avance se suma la incorporación de tecnologí …

Whoop, the maker of a wearable wristband, plans to use the funds for global expansion and personalized health features.

The company designed the lead to have the safety benefits of small-diameter devices without sacrificing durability.

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.

In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.